Morphocell Technologies Inc.

Morphocell Technologies is a regenerative medicine company developing an extensive therapeutic platform based on its stem cell-derived engineered tissues for organ replacement therapy. Through an allogeneic approach, strong preclinical data in small and large animals and key hurdles in manufacturing already de-risked, Morphocell is rapidly approaching the clinical phases. ReLiver®, our lead product, is an implantable, fully mature, engineered liver tissue that allows for the allogeneic treatment of acute and acute-on-chronic liver failure (a $14B market), without the need of immunosuppression. Supported by a $6M seed round and strong partnerships, ReLiver is now less than 36 months away from a first-in-human clinical trial. With 11 FTE, a solid IP position and new HQ and laboratories, Morphocell established its leadership in the liver cell therapy space. The company has started its fundraising for a series A financing round that will support its progression to the clinic.